Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Public Health Genomics: Public Health Public the European andand international contextHealth – the future of youth health care is being built today! Genomics Prof. dr. Angela Brand MD PhD MPH Angela Brand EUPHA 2008 Director of the Institute for Public Health Genomics (IPHG) @ UM PAOG 25.01..2011 Public Health versus Population Health Public Health Genomics – PAOG 25.01.2011 – A. Brand What is Public Health? Public Health Genomics – PAOG 25.01.2011 – A. Brand Public Health Trias [IOM, 1988] Public Health Genomics – PAOG 25.01.2011 – A. Brand Are our current (public) health strategies evidence-based? Public Health Genomics – PAOG 25.01.2011 – A. Brand The challenge? „Are we assuring the right health interventions (Health Needs Assessment, Health Technology Assessment) in the right way (PHELSI, Quality Management & Policy Impact Assessment) in the right order and at the right time (Priority Setting & Health Targets) in the right place?“ (Concept of Integrated Health Care & Health Management) Public Health Genomics – PAOG 25.01.2011 – A. Brand Obesity ... Public Health Genomics – PAOG 25.01.2011 – A. Brand … the obesity story • • • • • • • • • • • • • • epidemic pattern? infectious disease? adenovirus … bad condition? life expectancy … obesity – type 2 diabetes – innate immunity? subtypes? rare and common … genetic susceptibility regarding physical activity genetic susceptibility regarding appetite epigenomics nutrigenomics self-responsibility? empowerment? health literacy? discrimination? obesity versus overweight … obesity in relation to extreme underweight ? ??? Public Health Genomics – PAOG 25.01.2011 – A. Brand The complex interaction of the main determinants of health .. Public Health Genomics – PAOG 25.01.2011 – A. Brand … tackling health determinants and understanding genome-environmental interactions … Public Health Genomics – PAOG 25.01.2011 – A. Brand as early as possible ... Public Health Genomics – PAOG 25.01.2011 – A. Brand 2011 - Paradigm shift in Public Health / Healthcare due to genomics Public Health Genomics – PAOG 25.01.2011 – A. Brand … genomics is a „moving target“ … Public Health Genomics – PAOG 25.01.2011 – A. Brand … from the Human Genome Project to the Personal Genome Project … Public Health Genomics – PAOG 25.01.2011 – A. Brand Continuum of Genome-based Knowledge • • • • • • • • • • • • • Genetic diseases Inherited genetic variation – (polymorphisms) Narrow focus Somatic genetic information Pathogen/vector genome information – Genome vs. Genome Biological markers of all types Modern biology Epigenomics Non-linear networks in systems biology / biomedicine “Diseasomes” Interactoms Personal Genome Broad focus “Integrative Genomes” Multiplex genome engineering & synthetic genomes Highly Biotechnology and (computational) Bioinformatics driven! Public Health Genomics – PAOG 25.01.2011 – A. Brand Product and Process Innovation! Public Health Genomics – PAOG 25.01.2011 – A. Brand … need for translating biological complexity (1) into genome-based research (2) into health policies (3) into evidence-based health practice Public Health Genomics – PAOG 25.01.2011 – A. Brand Public Health Genomics (PHG) “Public Health Genomics (PHG) is the responsible and effective translation of genome-based knowledge and technologies into public policy and health services for the benefit of population health.” [Bellagio Statement 2005: GRAPHInt, PHGEN, IPHG] Public Health Genomics – PAOG 25.01.2011 – A. Brand Public Health Genomics (PHG) - a journey of 15 years … 1997 worldwide four centres of PHG: Muin Khoury (USA) Wylie Burke (USA) Ron Zimmern (UK) Angela Brand (Germany) 2011 IPHG@UM coordination: European Network (PHGEN) International Network (GRaPHint) Public Health Genomics – PAOG 25.01.2011 – A. Brand NIH Vision (1) Public Health Genomics – PAOG 25.01.2011 – A. Brand NIH Vision (2) Public Health Genomics – PAOG 25.01.2011 – A. Brand NIH Vision (3) Public Health Genomics – PAOG 25.01.2011 – A. Brand Paradigm shift in Public Health due to genomics - beyond the 4 P’s 1. from common complex diseases to “multiple rare diseases” 2. from diseases to “diseasomes” 3. from risk factor to “risk pattern” 4. from clinical utility to “personal utility” Public Health Genomics – PAOG 25.01.2011 – A. Brand Genome-Environment-Interactions [PHGF, UK, 2005] Heart disease PKU Schizophrenia Cancer Cystic fibrosis Duchenne muscular dystrophy Totally Genetic Fragile X Multiple Diabetes sclerosis Asthma Motor vehicle accident Alzheimer’s TB Struck by Meningococcus lightning Autism Obesity Rheumatoid arthritis Totally Environmental Public Health Genomics – PAOG 25.01.2011 – A. Brand phenotype (disease) = mix of totally different entities (e.g., breast cancer, obesity) Challenges Are we comparing apples with oranges? Are we overestimating the number of “common diseases” and underestimating the number of “rare diseases”? N =1 trials? Reimbursement of “rare health problems”? Public Health Genomics – PAOG 25.01.2011 – A. Brand Paradigm shift in Public Health due to Genomics - beyond the 4 P’s 1. from common complex diseases to “multiple rare diseases” 2. from diseases to “diseasomes” 3. from risk factor to “risk pattern” 4. from clinical utility to “personal utility” Public Health Genomics – PAOG 25.01.2011 – A. Brand health outcome = diseasome instead of disease (pleiotropic effect: e.g. IgG depletion in rheumatoid arthritis and B-cell lymphoma) Challenges Do we have to redefine diseases and ICD 10? Are we mixing cases and controls in epidemiology? Does this explain biases in epidemiology? Does this explain multimorbidity? Does this explain the effectiveness of drugs (here: Retuximab)? What kind of medical specialists do we need? “Diseasomists”? How to structure a hospital? Public Health Genomics – PAOG 25.01.2011 – A. Brand Diseasomes [PNAS 104:8677-8678, 2007] Public Health Genomics – PAOG 25.01.2011 – A. Brand PNAS 2007;104:8677-8678 Paradigm shift in Public Health due to Genomics - beyond the 4 P’s 1. from common complex diseases to “multiple rare diseases” 2. from diseases to “diseasomes” 3. from risk factor to “risk pattern” 4. from clinical utility to “personal utility” Public Health Genomics – PAOG 25.01.2011 – A. Brand genomic variant = risk factor and protective factor at the same time (e.g., ACE insertion-deletion polymorphism increases the risk of stroke and decreases the risk of Alzheimer’s disease) epigenomic effects = environmental factors can modify and trigger health outcomes by changing the genome (e.g., infectious diseases, social factors, soja milk) Challenges Are we still thinking of health determinants and risk factors in a deterministic way (genetic determinism and social determinism)? Shall we avoid to separate between infectious and non-infectious diseases? Are we for the first time in history able to understand the genome-environmental interplay and risk patterns? Are we able to “measure” the success of prevention? Public Health Genomics – PAOG 25.01.2011 – A. Brand Paradigm shift in Public Health due to Genomics - beyond the 4 P’s 1. from common complex diseases to “multiple rare diseases” 2. from diseases to “diseasomes” 3. from risk factor to “risk pattern” 4. from clinical utility to “personal utility” Public Health Genomics – PAOG 25.01.2011 – A. Brand Personal genome (e.g., permanent changing of the personal epigenome/(genome?) due to the influence of environmental factors) Challenges Individual pathways in systems biology correlate with onset, severity and prolongation of diseases as well as with responses to therapies. Does this mean “myself evidence” instead of EBM and RCT? Does this mean to proof “personal utility” instead of clinical utility? Do we have to offer and reimburse the right intervention for the right person at the right time? How to interpret and manage personal data? Role of Biobanks or Surveillance? Public Health Genomics – PAOG 25.01.2011 – A. Brand … paradigm shift in Public Health health promotion and prevention in public health risk groups or communities settings “one size fits all” prevention in public health genomics individuals family history lifestyle risks for “diseasomes” risk groups with similar risk patterns genomic profiling Public Health Genomics – PAOG 25.01.2011 – A. Brand Pharmacogenomics (Ilhan Celik, EHFG, 2010) Stratified Medicine is about adapting the treatment (molecule, dose, schedule,…) according to the patient’s characteristics for better efficacy and less adverse events. Stratified Medicine Personalized Medicine - Patient sub-population e.g. molecular testing for tumor mutation - Individual patients versus e.g. cancer vaccine made from the patient’s tumor Public Health Genomics – PAOG 25.01.2011 – A. Brand Epigenomics: The missing link between Environment and Biomedicine? (1) >> ability of all environmental factors to gene expression and phenotype change >> ability to understand genome-environment interactions >> ability to measure genome-environment interactions >> ability of early diagnosis of individuals for adult-onset disease >> ability of novel preventive and therapeutic approaches in an asymptomatic health status Public Health Genomics – PAOG 25.01.2011 – A. Brand Epigenomics: The missing link between Environment and Biomedicine? (2) >> need for a comprehensive personal health information model >> need for the implementation of intraindividual monitoring & surveillance systems (individual health management) >> what (epigenomic) information is relevant for which person at what time during the lifespan for what purpose? >> need for personalized healthcare >> need to look not only “from cell to society”, but also “from society to cell” >> … need for strong public health leadership! Public Health Genomics – PAOG 25.01.2011 – A. Brand “… we face a time when the taxonomy of human disease is being redefined given the existence of pathological and molecular disease subtypes…” [Nuria Malats, CNIO 2009] … we face a time when boundaries of disciplines are crossed and the understanding of diseases is changed as it happened before with the jump from the macroscopic view in anatomy to the microscopic view in cell structure … Let’s get prepared in time – the future is built today! Public Health Genomics – PAOG 25.01.2011 – A. Brand Child & Youth Health? … 4 examples … Public Health Genomics – PAOG 25.01.2011 – A. Brand Child & Youth Health - PHG 1. obesity > insights into a complex and global phenomenon Public Health Genomics – PAOG 25.01.2011 – A. Brand Child & Youth Health - PHG 2. asthma > insights into misclassification of diseases and the consequences of misclassification Public Health Genomics – PAOG 25.01.2011 – A. Brand Child & Youth Health - PHG 3. cancer > options for personalized healthcare Public Health Genomics – PAOG 25.01.2011 – A. Brand Child & Youth Health - PHG 4. newbornscreening > technology driven innovations and their consequences Public Health Genomics – PAOG 25.01.2011 – A. Brand … on the international level? Public Health Genomics – PAOG 25.01.2011 – A. Brand Public Health Genomics – PAOG 25.01.2011 – A. Brand … on the European level? Public Health Genomics – PAOG 25.01.2011 – A. Brand http://www.phgen.eu Public Health Genomics – PAOG 25.01.2011 – A. Brand PHGEN II (DG SANCO) … To produce the first edition of "European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies" using an interdisciplinary and stakeholder approach … reviewing the available evidence including evidence emerging from relevant European research and health action networks. … covering all EU Member States, Applicant Countries, and EFTA-EEA Countries Public Health Genomics – PAOG 25.01.2011 – A. Brand PHGEN II challenges and USPs? We have to define today and tomorrow what kind of (policy) „guidelines“ we can and should aim for! … taking into account e.g. • dynamics of the field: genomics is a „ moving target“ (from HG to PG) • genome-environment interactions changing permanantly over time and space (incl. epigenomics: „from cell to society to cell“) • systems network thinking of biomedicine and environment (incl. social environment): e.g. „diseasomes“ and „social networks“ • P4 medicine (predictive, preemtive, personalised, participatory): „a change of view that changes everything“ Public Health Genomics – PAOG 25.01.2011 – A. Brand Policy Advice GRaPH-Int Public Population Project in Genomics JRC-IPTS OECD PHG journal European Health Forum Gastein ECDC European Observatory on Health Systems and Policies EC Research & DG SANCO EUPHA European Science Foundation Public Health Genomics – PAOG 25.01.2011 – A. Brand (16.06.2010) Institute for Public Health Genomics – Department of Genetics & Cell Biology … the national level? Public Health Genomics – PAOG 25.01.2011 – A. Brand PHGEN National Task Forces June, 19th 2006 – NTF Turkey July, 10th 2006 – NTF Italy November, 3rd 2006 – NTF Portugal November, 24th 2006 – NTF Germany November, 29th 2006 – NTF Belgium January, 12th 2007 – NTF Spain January, 24th 2007 – NTF Netherlands September, 25th 2007 – NTF Czech Republic October, 19th 2007 – NTF Bulgaria November, 20th 2007 – NTF Norway January, 30th 2008 – NTF Poland April, 23rd 2008 – NTF Hungary August 28th 2009 – NTF Switzerland 2010 – NTF Croatia … in preparation: Slovenia, Iceland, Malta, Sweden, France … Public Health Genomics – PAOG 25.01.2011 – A. Brand PHG in National Instituts of Public Health Germany Belgium Italy Poland Finnland Croatia The Netherlands? … • platform for the development of national strategies • vehicle for the promotion of sustainability Public Health Genomics – PAOG 25.01.2011 – A. Brand Thanks for your attention ! Public Health Genomics – PAOG 25.01.2011 – A. Brand